Literature DB >> 10679647

Menstrual and reproductive factors and risk of soft tissue sarcomas.

F Fioretti1, A Tavani, S Gallus, E Negri, S Franceschi, C La Vecchia.   

Abstract

BACKGROUND: Soft tissue sarcomas (STS) are a heterogeneous group of neoplasms whose etiology remains largely undefined. A role for female hormones in the development of STS has been suggested. To investigate this possibility, the authors analyzed data from a hospital-based case-control study conducted in Northern Italy between 1983 and 1998.
METHODS: Cases were 104 women aged < 79 years with incident STS who were admitted to the cancer institutes and major teaching and general hospitals. Controls were 505 women admitted to the same network of hospitals for acute, nonneoplastic, nongynecologic, and nonimmune-related conditions.
RESULTS: The multivariate odds ratio (OR) for women aged >/= 15 years compared with those aged < 12 years at menarche was 1.94 (95% confidence intervals [95% CI], 0.80-4.74). No association with STS risk was observed for menstrual cycle pattern, age at menopause, parity, and abortions. Late age at first pregnancy and birth were found to be related to an increased risk of STS, with an OR of 3.16 (95% CI, 0. 96-10.44) and 2.79 (95%% CI, 0.79-9.90) for women aged >/= 30 years at first pregnancy and birth compared with those aged < 20 years. The trend in risk was significant for age at first pregnancy. No relation with the risk of STS emerged for age at last birth and time since first or last birth.
CONCLUSIONS: The risk of STS was found to be weakly related to late age at first pregnancy or birth, but not to other menstrual and reproductive factors. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 10679647     DOI: 10.1002/(sici)1097-0142(20000215)88:4<786::aid-cncr8>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence.

Authors:  R Troisi; T Bjørge; M Gissler; T Grotmol; C M Kitahara; S M Myrtveit Saether; A G Ording; C Sköld; H T Sørensen; B Trabert; I Glimelius
Journal:  J Intern Med       Date:  2018-03-25       Impact factor: 8.989

2.  A 3-DNA methylation signature as a novel prognostic biomarker in patients with sarcoma by bioinformatics analysis.

Authors:  Xiao-Wei Wang; Qi Sun; Shi-Bin Xu; Chao Xu; Chen-Jie Xia; Qi-Ming Zhao; Hua-Hui Zhang; Wei-Qiang Tan; Lei Zhang; Shu-Dong Yao
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

3.  Incidence, Treatment and Outcome of Patients with Retroperitoneal Soft-Tissue Sarcoma in Switzerland 2005-2015: A Population-Based Analysis.

Authors:  Johanna C F Willburger; Marco von Strauss; Caspar J Peterson; Tracy R Glass; Christoph Kettelhack
Journal:  World J Surg       Date:  2021-11-09       Impact factor: 3.352

4.  Epidemiology and therapies for metastatic sarcoma.

Authors:  Ernest K Amankwah; Anthony P Conley; Damon R Reed
Journal:  Clin Epidemiol       Date:  2013-05-16       Impact factor: 4.790

5.  The epidemiology of sarcoma.

Authors:  Zachary Burningham; Mia Hashibe; Logan Spector; Joshua D Schiffman
Journal:  Clin Sarcoma Res       Date:  2012-10-04

6.  A sarcoma at the site of previous extravasation of adriamycin.

Authors:  Joris Ceulemans; Ivo De Wever; Raf Sciot; Maria Debiec-Rychter; Allan T van Oosterom
Journal:  Sarcoma       Date:  2002
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.